Multiple switching of biosimilars a sticking point: ARA

The PBAC’s commitment to evidence demonstrated at a biosimilar stakeholder meeting this week is reassuring but the potential for patients to be switched between drugs multiple times remains a concern, the ARA says. ARA President Mona Marabani attended the meeting on Tuesday along with other groups including the Gastroenterological Society of Australia, the Royal Australasian ...

Already a member?

Login to keep reading.

© 2021 the limbic